This research aims to evaluate whether eligibility criteria effectively identify patients with low risk of upgrading from ductal carcinoma in situ to invasive carcinoma.
Analyzed existing active monitoring trials for ductal carcinoma in situ
Identified specific eligibility criteria used
Reviewed predictive biomarkers relevant to DCIS lesions
Current criteria may not accurately exclude all patients at risk for invasive carcinoma
Better predictive biomarkers are needed to improve patient stratification
Findings could enhance criteria for active monitoring programs
Abstract
More precise criteria and predictive biomarkers are needed to better stratify DCIS lesions and exclude women harboring invasive carcinomas from AM regimens.